Thiopurines such as azathioprine (AZA) and 6-mercaptopurine are frequently used for the treatment of inflammatory bowel diseases. Patients with low or absent thiopurine S-methyltransferase (TPMT) activity, resulting in high 6-thioguanine nucleotide levels, have an increased risk of developing leukopenia. Alternatively, certain viral infections could induce leukopenia. We present the case of an adult Crohn’s disease patient with a parvovirusB19 infection and leukopenia during long-term AZA therapy. The uncomplicated long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia. ParvovirusB19 was assumed to induce the leukopenia by restraining myeloid proliferation. In addition, AZA probably potentiated susceptibility to this viral infection and may have inhibited adequate immunological defense. Leukopenia during thiopurine therapy not explained by TPMT deficiency could be induced by parvovirusB19 infection and compels temporal but not permanent cessation of thiopurine therapy.

Keywords:
Azathioprine, Crohn’s disease, Leukopenia, Parvovirus B19
1.
Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000;2:CD000067.
2.
Timmer A, McDonald JW, MacDonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1):CD000478.
3.
Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025–1030.
4.
Gisbert JP, Gomollon F: Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103:1783–1800.
5.
Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705–713.
6.
Sahasranaman S, Howard D, Roy S: Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008;64:753–767.
7.
Gilissen LP, Derijks LJ, Verhoeven HM, Bierau J, Hooymans PM, Hommes DW, Engels LG: Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn’s disease. Dig Liver Dis 2007;39:182–186.
8.
Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, Pousette A, Almer S: Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006;55:1423–1431.
9.
Roberts RL, Gearry RB, Bland MV, Sies CW, George PM, Burt M, Marinaki AM, Arenas M, Barclay ML, Kennedy MA: Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genomics 2008;18:434–438.
10.
Korelitz BI, Zlatanic J, Smith MJ, Lipe RJ, Baiocco PJ, Gleim GW: Significance of WBC differential when leukopenia is induced by 6-MP for IBD. Gastroenterology 1997;113:1810–1811.
11.
Green M, Michaels MG: Infectious complications of immunosuppressive medications in organ transplant recipients. Pediatr Infect Dis J 2007;26:443–444.
12.
de Boer NK, van Bodegraven AA, de Graaf P, van der Hulst RW, Zoetekouw L, van Kuilenburg AB: Paradoxical Elevated Thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. Ther Drug Monit 2008;30:390–393.
13.
Cossart YE, Field AM, Cant B, Widdows D: Parvovirus-like particles in human sera. Lancet 1975;1:72–73.
14.
Jordan JA: Human Parvoviruses; in Murray PR, Baron EJ, Jorgenson JH, Landry M, Pfaller MA (eds): Manual of Clinical Microbiology. Washington, ASM Press, 2007, vol 9, pp 1622–1630.
15.
Brown KE, Young NS: Parvovirus B19 infection and hematopoiesis. Blood Rev 1995;9:176–182.
16.
Muir K, Todd WT, Watson WH, Fitzsimons E: Viral-associated haemophagocytosis with parvovirus-B19-related pancytopenia. Lancet 1992;339:1139–1140.
17.
Heegaard ED, Schmiegelow K: Serologic study on parvovirus b19 infection in childhood acute lymphoblastic leukemia during chemotherapy: clinical and hematologic implications. J Pediatr Hematol Oncol 2002;24:368–373.
18.
Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS: Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988;ii:1159–1162.
19.
Istomin V, Sade E, Grossman Z, Rudich H, Sofer O, Hassin D: Agranulocytosis associated with parvovirus B19 infection in otherwise healthy patients. Eur J Intern Med 2004;15:531–533.
20.
Herzog-Tzarfati K, Shiloah E, Koren-Michowitz M, Minha S, Rapoport MJ: Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins. Eur J Intern Med 2006;17:439–440.
21.
Scheurlen W, Ramasubbu K, Wachowski O, Hemauer A, Modrow S: Chronic autoimmune thrombopenia/neutropenia in a boy with persistent parvovirus B19 infection. J Clin Virol 2001;20:173–178.
22.
Barlow GD, McKendrick MW: Parvovirus B19 causing leucopenia and neutropenia in a healthy adult. J Infect 2000;40:192–195.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.